title: Bovine lactoferrin in preventing preterm delivery associated with sterile inflammation.
abstract: Preterm delivery (PTD) occurs before the 37th week of gestation. Iron deficiency anemia and inflammatory processes either related to infection or sterile inflammatory response represent risk factors for PTD. Bovine lactoferrin (bLf), an emerging important regulator of iron and inflammatory homeostasis, can represent a new therapeutic approach for PTD treatment. Here an open-label cohort and subcohort study is reported. The cohort was designed to assess the effect of bLf oral administration on iron and inflammatory homeostasis in anemic pregnant women. The subcohort including women of the cohort with PTD threat was additionally treated with bLf intravaginal administration. A significant improvement of hematological parameters was observed in the women's cohort together with a consistent decrease of serum interleukin-6 (IL-6) levels. Combined administration of oral and intravaginal bLf to the women's subcohort with PTD threat decreased IL-6 in both serum and cervicovaginal fluids, cervicovaginal prostaglandin F(2α), and suppressed uterine contractility. BLf administration blocked further shortening of cervical length and the increase of fetal fibronectin thus prolonging the length of pregnancy. The deliveries occurred between the 37th and 38th week of gestation. These results provide strong evidence for a role of bLf in PTD treatment, thus extending the therapeutic potential of this multifunctional natural protein.
authors.affiliation: Department of Woman Health and Territorial Medicine, Sapienza University of Rome, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.
authors.forename: Rosalba
authors.initials: R
authors.lastname: Paesano
authors.forename: Miriam
authors.initials: M
authors.lastname: Pietropaoli
authors.forename: Francesca
authors.initials: F
authors.lastname: Berlutti
authors.forename: Piera
authors.initials: P
authors.lastname: Valenti
mesh_terms: D000282:Administration, Intravaginal; D000284:Administration, Oral; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy*; D000818:Animals; D002417:Cattle; D002584:Cervix Uteri / Q000187:drug effects / Q000378:metabolism; D015237:Dinoprost / Q000378:metabolism; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D015850:Interleukin-6 / Q000097:blood / Q000378:metabolism; D007781:Lactoferrin / Q000008:administration & dosage*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000188:drug therapy*; D047928:Premature Birth / Q000209:etiology / Q000517:prevention & control*; D012307:Risk Factors; D016896:Treatment Outcome; D002575:Uterine Cervicitis / Q000188:drug therapy*
chemical_list: D007155:Immunologic Factors; D015850:Interleukin-6; D015237:Dinoprost; D007781:Lactoferrin